Compare RGEN & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGEN | CFR |
|---|---|---|
| Founded | 1981 | 1868 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.1B |
| IPO Year | N/A | N/A |
| Metric | RGEN | CFR |
|---|---|---|
| Price | $156.66 | $128.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 15 |
| Target Price | ★ $170.90 | $138.33 |
| AVG Volume (30 Days) | ★ 724.0K | 441.1K |
| Earning Date | 10-28-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.10% |
| EPS Growth | N/A | ★ 20.47 |
| EPS | 0.03 | ★ 9.72 |
| Revenue | $707,890,000.00 | ★ $2,141,575,000.00 |
| Revenue This Year | $17.84 | $14.17 |
| Revenue Next Year | $12.57 | $4.47 |
| P/E Ratio | $5,097.58 | ★ $13.29 |
| Revenue Growth | ★ 11.74 | 9.02 |
| 52 Week Low | $102.97 | $100.31 |
| 52 Week High | $182.52 | $146.44 |
| Indicator | RGEN | CFR |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 60.18 |
| Support Level | $160.11 | $125.01 |
| Resistance Level | $165.02 | $131.54 |
| Average True Range (ATR) | 4.97 | 2.35 |
| MACD | -1.27 | 0.67 |
| Stochastic Oscillator | 7.12 | 74.32 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of mid-2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.